Piper Jaffray Remains Bullish on Collegium Pharma (COLL) Ahead of FDA Committee Meeting
Tweet Send to a Friend
Piper Jaffray reiterated an Overweight rating and $34.00 price target on Collegium Pharmaceutical (NASDAQ: COLL) following the FDA's recent release ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
